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Abstract
 
Type I interferons (IFNs) are cytokines exhibiting antiviral and antitumor effects, including
multiple activities on immune cells. However, the importance of these cytokines in the early
events leading to the generation of an immune response is still unclear. Here, we have investi-
gated the effects of type I IFNs on freshly isolated granulocyte/macrophage colony-stimulating
factor (GM-CSF)–treated human monocytes in terms of dendritic cell (DC) differentiation and
activity in vitro and in severe combined immunodeficiency mice reconstituted with human pe-
ripheral blood leukocytes (hu-PBL-SCID) mice. Type I IFNs induced a surprisingly rapid mat-
uration of monocytes into short-lived tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL)–expressing DCs endowed with potent functional activities, superior with re-
 
spect to the interleukin (IL)-4/GM-CSF treatment, as shown by FACS
 
®
 
 analyses, mixed leu-
kocyte reaction assays with allogeneic PBLs, and lymphocyte proliferation responses to HIV-1–
pulsed autologous DCs. Type I IFN induced IL-15 production and strongly promoted a T
helper cell type 1 response. Notably, injection of IFN-treated HIV-1–pulsed DCs in SCID
mice reconstituted with autologous PBLs resulted in the generation of a potent primary im-
mune response, as evaluated by the detection of human antibodies to various HIV-1 antigens.
These results provide a rationale for using type I IFNs as vaccine adjuvants and support the
concept that a natural alliance between these cytokines and monocytes/DCs represents an im-
portant early mechanism for connecting innate and adaptive immunity.
Key words: interferon • dendritic cell maturation and activation • monocytes • SCID mice • 
immunity
 
Introduction
 
Understanding the mechanisms involved in the initiation of
the immune response is a crucial issue in immunology with
important implications for vaccine development. Dendritic
 
cells (DCs)
 
1
 
 are the most potent antigen-presenting cells
playing a pivotal role in the induction of the immune re-
sponse (1–3). DCs are derived from hematopoietic progeni-
tor cells (1, 2), and are considered the “sentinels” of the im-
mune system (3). Immature DCs are generally located in
peripheral tissues, in sites where they can optimally survey
for incoming pathogens. The interaction of DCs with
pathogens leads to migration to secondary lymphoid organs
where they can initiate a specific T cell response. This com-
plex process is associated with differentiation and functional
activation of DCs (2, 3). Recently, improved methods for
the in vitro generation of large numbers of DCs from pe-
ripheral blood monocytes have been established, thus allow-
 
ing a more precise characterization of the events leading
to maturation and activation of DCs under well-defined
experimental conditions. Of interest, recent results indicate
 
that DC maturation can occur directly from monocytes
during transendothelial migration (4). However, the in vivo
relevance of monocyte differentiation into DCs remains un-
clear. Likewise, the early mechanisms and factors naturally
involved in the regulation of differentiation, activation, and
survival of DCs from monocytes under physiological condi-
tions or in response to infections are still largely unknown.
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Abbreviations used in this paper:
 
 AT, aldrithiol; CIFN, consensus IFN;
DC, dendritic cell; ELISPOT, enzyme-linked immunospot; GFP, green
fluorescent protein; hu, human; RT, reverse transcription; s, soluble;
TRAIL, TNF-related apoptosis-inducing ligand. 
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Type I IFNs are cytokines spontaneously expressed at
low levels under normal physiological conditions (5),
whose expression is highly enhanced soon after cell expo-
sure to viruses or other stimuli (6). Because of their potent
direct antiviral activity, which is combined with stimula-
tory effects on NK cells, type I IFNs are considered impor-
tant mediators of the innate immunity (7). Recently, it has
been reported that the so-called “natural IFN-producing
cells” (IPCs), whose nature had remained elusive for many
years, are represented by CD4
 
1
 
CD11c
 
2
 
 type 2 DC precur-
sors (pDC2s) (8), also defined as plasmacytoid monocytes
(9), which produce unusually high amounts of type I IFN
after microbial challenge.
Originally considered as simple antiviral substances, type
I IFNs (especially IFN-
 
a
 
) have recently been reconsidered
as important cytokines for the generation of a protective T
cell–mediated immune response to virus infections and tu-
mor growth (10). In particular, an ensemble of data ob-
tained in different model systems has pointed out the im-
portance of type I IFN in enhancing antibody production
(11) and supporting the proliferation, functional activity,
and survival of certain T cell subsets (12–16). Although
scattered data suggesting a promoting effect of type I IFN
on DC maturation have recently been reported (17–19),
the role of the IFN system in the differentiation, functional
activities, and survival of DCs has remained unclear.
In this study, we have investigated whether type I IFNs
can represent an early and important player regulating the
differentiation and activation of DCs from monocytes cul-
tured in the presence of GM-CSF. We report that type I
IFNs rapidly induce the differentiation of monocytes into
DCs endowed with potent functional activities both in
vitro and in vivo,
 
 
 
by
 
 
 
using the chimeric model of SCID
mice reconstituted with human PBLs (20). DCs generated
in the presence of type I IFN spontaneously produced con-
siderable amounts of IL-15 and induced a Th1-biased im-
mune response. Remarkably, DCs generated in the pres-
ence of IFN and pulsed with inactivated HIV-1 were
capable of inducing a potent primary immune response in
hu-PBL-SCID mice, as revealed by the appearance of high
levels of human antibodies against a wide spectrum of
HIV-1 proteins. On the whole, these results demonstrate
that type I IFNs are powerful factors responsible for the
rapid differentiation of monocytes into DCs endowed with
potent functional activities, supporting the concept that a
natural alliance between these cytokines and monocytes/
DCs represents an important mechanism for regulating in-
nate and adaptive immunity.
 
Materials and Methods
 
Cell Separation and Culture.
 
Peripheral blood mononuclear
cells were obtained from heparinized blood of normal donors by
Ficoll density gradient centrifugation (Seromed). Monocytes
were obtained either by 2 h adhesion in 25–75-cm
 
2
 
 flasks (Co-
star), or by standard Percoll density gradient centrifugation. In the
majority of the experiments, monocytes were further enriched by
depleting contaminating cells using negative immunoselection by
 
anti–mouse Ig–conjugated magnetic beads (Dynal), incubating
the cells for 30 min at 4
 
8
 
C with azide-free antibodies (0.5 
 
m
 
g/10
 
6
 
cells) to human CD3, CD19, and CD56 antigens (BD PharMin-
gen). After this procedure, the resulting cell population was rep-
resented by 
 
.
 
98% CD14
 
1
 
 monocytes, as assessed by flow cytom-
etry. Blood-derived monocytes were plated at the concentration
of 1–2 
 
3 
 
10
 
6 
 
cells/ml in RPMI 1640 (GIBCO BRL) supple-
mented with 10% FCS. The following cytokines were added
alone or in combination: GM-CSF (500 U/ml), IL-4 (1,000
U/ml; R&D Systems), and type I IFN (500–1,000 U/ml). In the
majority of the experiments illustrated in this paper, we used con-
sensus
 
 
 
IFN (CIFN, specific activity of 10
 
9
 
 U/mg protein) (21)
provided by Amgen. CIFN is a synthetic type I IFN produced
from recombinant DNA, whose sequence is based on a consensus
derived from the amino acid sequences of the most common
types of human IFN-
 
a
 
. In a series of experiments, IFN-
 
a
 
2b
(PeproTech) and IFN-
 
b
 
 (Serono) were also used. All of the IFN
preparations used in this study were shown to be free of any de-
tectable LPS contamination. After 3 and 6 d of culture, nonad-
herent and loosely adherent cells were collected and used for sub-
sequent analysis. To assess terminal maturation, cells were
cultured for an additional 2 d in the presence of the appropriate
cytokine combination and LPS (1 
 
m
 
g/ml; Sigma-Aldrich).
 
Immunophenotypic Analysis.
 
Cells were washed and resus-
pended in PBS containing 1% human serum and incubated with a
series of fluorochrome-conjugated mAbs to human antigens for
30 min at 4
 
8
 
C. The following mAbs were used for immunofluo-
rescent staining: anti-CD14, CD11c, CD54, CD80, HLA-DR,
CD95 (Fas) (Becton Dickinson), CD1a, CD40, CD86, Fas-L
(NOK-1), (BD PharMingen), and CD83 (Immunotech). Cells
were analyzed by flow cytometry. Data was collected and ana-
lyzed by using a FACSort™ (Becton Dickinson) flow cytometer,
and data analysis were performed by CELLQuest™ software
(Becton Dickinson). Cells were electronically gated according to
light scatter properties in order to exclude cell debris and contam-
inating lymphocytes.
 
MLR.
 
Monocyte-depleted PBLs were seeded into 96-well
plates (Costar) at 10
 
5
 
 cells/well. Purified allogeneic DCs (5 
 
3
 
10
 
3
 
) were added to each well in triplicate. After 5 d, 1 mCi
of [methyl-
 
3
 
H]thymidine (Amersham Pharmacia Biotech) was
added to each well and incubation was continued for an addi-
tional 18 h. Cells were finally collected by a Mach II Mcell
(Tomtec) harvester and thymidine uptake was quantitated by liq-
uid scintillation counting on a 1205 Betaplate (Amersham Phar-
macia Biotech).
 
ELISA for IFN-
 
g
 
 and Other Cytokines.
 
Commercial ELISAs
(R&D Systems) were used to quantitate human IFN-
 
g
 
, IL-4, IL-
12, and IL-15. ELISAs were performed in triplicate, and labora-
tory standards were included on each plate. Assay sensitivity was
as follows: IFN-
 
g
 
 (3 pg/ml), IL-4 (10 pg/ml), IL-12 (0.5 pg/ml),
and IL-15 (1 pg/ml).
 
Reverse Transcription PCR.
 
The mRNA from DCs was ex-
tracted by RNAzol B and processed as described previously
(22). Transcripts were detected by amplifying the retrotrans-
cribed RNA with specific primer pairs for IL-1
 
b
 
 (sense,
CTTCATCTTTGAAGAAGAACCTATCTTCTT; antisense,
AATTTTTGGGATCTACACTCTCCAGCTGTA), TNF-
 
a
 
(sense, ATGAGCACTGAAAGCATGATCCGG; antisense,
GCAATGAT-CCCAAAGTAGACCTGCCC), IL-12 p40 (sense,
CCAAGAACTTGCAGCTGAAGA; sense, TGGGTCTAT-
TCCGTTGTGTC), IL-15 (sense, CTCGTCTAGAGCCAA-
CTGGGTGAATGTAATAAG; antisense, TACTTACTCG-
AGGAATCAATTGCAATCAAGAAGTG), and IL-18 (sense, 
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TCTGACTGTAGAGATAATGC; antisense, GAACAGTGAA-
CATTATAGATC). Primer sequences for TNF-related apopto-
sis-inducing ligand (TRAIL) and TRAIL receptors (R1, R2, R3,
and R4) are reported elsewhere (23). The samples were amplified
for 30–35 cycles at the following conditions: 94
 
8
 
C for 40 s, 62
 
8
 
C
for 40 s, and 72
 
8
 
C for 40 s. Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) reverse transcription (RT)-PCR was run in
parallel to normalize the levels of human RNA in all the samples.
All RT-PCR and products were in the linear range of amplifica-
tion.
 
Apoptosis Detection.
 
Apoptosis was detected by staining with
ApoAlert™ Annexin V-green fluorescent protein (GFP) (CLON-
TECH Laboratories, Inc.) according to the manufacturer’s in-
structions. Cells were analyzed by flow cytometry on a FAC-
Sort™ (Becton Dickinson).
 
DC-mediated Killing of Human Tumor Cells and Evaluation of
the Functional Significance of TRAIL Expression.
 
Monocytes were
cultured in the presence of IFN/GM-CSF for 5 d, washed, and
resuspended in complete medium. DCs were then incubated for
12 h with human CD4
 
1
 
 Jurkat cells as targets (E/T ratio of 4:1).
As a positive control for susceptibility of Jurkat cells to TRAIL-
induced death, 0.1 
 
m
 
g/ml of soluble (s)TRAIL, and 2 
 
m
 
g/ml of
enhancer antibody (Alexis) were added to target cells. In parallel
cultures, 1 
 
m
 
g/ml TRAIL-R2/Fc (Alexis) was added to DC ef-
fector cells 15 min before adding tumor cells in order to specifi-
cally inhibit TRAIL-mediated killing. Apoptotic cell death of Jur-
kat cells was evaluated by flow cytometry using Annexin V-GFP
(CLONTECH Laboratories, Inc.) and CD11c-PE (Becton Dick-
inson) staining. Cells were gated according to light scatter charac-
teristics and absence of CD11c expression.
 
Induction of Primary Response to HIV-1 Antigens and Proliferation
Assay.
 
HIV-1 SF162 strain was inactivated by aldrithiol (AT)-2
following a procedure recently described by Rossio et al. (24) and
stored at 
 
2
 
140
 
8
 
C until use. PBLs (4 
 
3
 
 10
 
6
 
) were stimulated with
10
 
6
 
 autologous DCs generated by treatment with either IFN/
GM-CSF or IL-4/GM-CSF for 3 d and pulsed with AT-2–inac-
tivated HIV-1 (40 ng of p24) for 2 h at 37
 
8
 
C. PBLs were restim-
ulated 7 d later with inactivated virus–pulsed DCs. Proliferation
assay was performed as follows: 5 
 
3
 
 10
 
3
 
 HIV-1–pulsed DCs were
added to 10
 
5
 
 autologous PBLs into triplicate wells. After 6 d, 1
mCi of [methyl-
 
3
 
H]thymidine (Amersham Pharmacia Biotech)
was added to each well and incubation was continued for an ad-
ditional 18 h. Cells were collected and thymidine uptake was
quantitated as described above.
 
Enzyme-linked Immunospot Assay.
 
Enzyme-linked immuno-
spot (ELISPOT) assay (Euroclone) was performed according to
the manufacturer’s instructions. In brief, 96-well plastic plates
(Maxisorp Nunc) were coated with capture anti–IFN-
 
g
 
 antibod-
ies and blocked with 2% BSA. 10-fold dilutions (from 10
 
5
 
 to 10
 
2
 
)
of PBLs from primary cultures were restimulated overnight with
DCs pulsed with inactivated HIV-1, added to triplicate wells, and
incubated for 18 h. After cell removal, plates were incubated with
an anti–IFN-
 
g
 
 detection biotinylated antibody and streptavidin-
conjugated alkaline phosphatase. Then, substrate solution was
added and the frequency of IFN-
 
g
 
–producing cells was evaluated
by enumerating single spots on an inverted microscope.
 
Hu-PBL-SCID Mouse Model.
 
CB17 scid/scid female mice
(Harlan) were used at 4 wk of age and kept under specific patho-
gen-free conditions. SCID mice were housed in microisolator
cages and all food, water, and bedding were autoclaved before
use. Hu-PBLs were obtained from the peripheral blood of
healthy donors. All donors were screened for HIV-1 and hepatitis
before donation. The hu-PBLs were obtained by Ficoll-Paque
 
density gradient centrifugation. 20 
 
3
 
 10
 
6
 
 cells were resuspended
in 0.5 ml RPMI 1640 medium and injected intraperitoneally into
the recipient mice. Mice were injected intraperitoneally with 1.5 
 
3
 
10
 
6
 
 autologous DCs, pulsed for 2 h at 37
 
8
 
C with AT-2–inacti-
vated HIV-1 (40 ng of p24). 7 d later, mice were given a boost
dose of AT-2–inactivated HIV-pulsed DCs. At days 7 and 14,
sera from hu-PBL-SCID mice were assayed for the presence of
human anti-HIV antibodies.
 
ELISA for Human Igs.
 
An ELISA system was used to quanti-
tate human total Igs, IgM, IgG1, and IgG4 Igs in the sera of the
chimeras by using anti–human total Ig and anti-IgM from Cap-
pel-Cooper Biomedical, anti-IgG1, or anti-IgG4 (BD PharMin-
gen). All ELISAs were performed in duplicate, and laboratory
standards were included on each plate. Sera from nonreconsti-
tuted SCID mice were used as negative controls of all the
ELISA determinations. ELISA for detection of specific anti-HIV
antibodies was performed using a specific peptide (i.e.,
ERYLKDQQLLGIWGCSGKLIC) corresponding to amino ac-
ids 591–611 of the HIV-1 gp41 protein (25).
 
 
 
Synthetic peptides
were immobilized on Dynatec (Dynal) microtiter plates by an
overnight incubation at 4
 
8
 
C. Serially diluted mouse sera were
added and incubated for 90 min at room temperature. Finally,
binding was revealed by reading A
 
490
 
 values after incubation with
substrate chromogen. Values represent mean adsorbence value of
each individual serum tested in duplicate. The cut-off value was
calculated as mean adsorbence value of all the control sera plus
0.100 A. Sera showing A
 
490
 
 values higher than this threshold
were considered positive for anti-HIV antibodies.
 
Western Blot.
 
Pooled sera from hu-PBL-SCID mice infected
with HIV-1–pulsed DCs were assayed by Western blot (HIV
Western blot kit; Cambridge Biotech). In brief, individual nitro-
cellulose strips were incubated overnight with different mouse se-
rum samples (diluted 1:20) or with a human positive control se-
rum (diluted 1:1,000). Visualization of the human Igs specifically
bound to HIV-1 proteins was obtained by incubation with sub-
strate chromogen after the addition of biotin-conjugated goat
anti–human IgG and streptavidin-conjugated horseradish peroxi-
dase.
 
Results
 
Characterization of DCs Differentiated from Monocytes in the
Presence of Type I IFN and GM-CSF.
 
In a first set of ex-
periments, we verified whether the addition of type I IFN
together with GM-CSF to blood-derived monocytes could
result in differentiation towards the DC phenotype com-
pared with the effects achievable after the standard treat-
ment with GM-CSF and IL-4, currently used for obtaining
immature DCs from monocytes (2, 26). In response to
IFN/GM-CSF treatment, adherent monocytes rapidly be-
came floating nonadherent cells within 3 d. The loss of ad-
herence was associated with cellular aggregation, and large
cell clusters were detected in the IFN/GM-CSF–treated
cultures, while a large part of IL-4/GM-CSF–treated cells
were still firmly adherent to the plastic surface. After 3 and
6 d of culture, cells treated with either IFN/GM-CSF or
IL-4/GM-CSF were analyzed for the expression of surface
markers associated with DC differentiation as well as of the
monocytic marker CD14. Fig. 1 A illustrates the mean flu-
orescence values of a series of selected markers upon treat-
ment of monocytes with either IFN/GM-CSF or IL-4/ 
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GM-CSF. The upregulation of costimulatory molecules
(CD80, CD86, and CD40) was consistently higher in IFN/
GM-CSF–treated cells than in cultures treated with IL-4/
GM-CSF as early as 3 d after cytokine treatment. As shown
in Fig. 1 B, the optimal enhancing effects on the expression
of costimulatory molecules were observed with IFN doses
ranging from 500 to 1,000 U/ml, while 100 U/ml of IFN
did not result in any significant difference compared with
cultures treated with GM-CSF alone (data not shown).
Comparable enhancing effects on DC phenotype were ob-
served using three different preparations of type I IFNs
 
(i.e., CIFN, IFN-
 
a
 
2b, and IFN-
 
b
 
)
 
 added in conjunction
with GM-CSF to blood-derived monocytes for 3 d of cul-
ture (Fig. 1 C).
Fig.
 
 
 
2 A shows the comparison of the representative
FACS
 
®
 
 profiles obtained at 3 d of cytokine treatment. No-
tably, cultures treated with IFN showed not only a marked
upregulation of costimulatory molecules and HLA-DR an-
tigen, but also a clear-cut induction of the expression of the
CD83 antigen (30–40% of positive cells), which is consid-
ered as a marker of mature/activated DCs. On the con-
trary, this marker was expressed only by a strict minority of
Figure 1. Upregulation of CD80, CD86, and
CD40 expression in DCs generated in the presence
of type I IFN and GM-CSF. (A) Comparison with
the effects induced by IL-4/GM-CSF at 3 and 6 d of
culture. Freshly isolated monocytes were prepared as
described in Materials and Methods. Cells were
treated with GM-CSF (500 U/ml) and with 1,000
U/ml of either CIFN or IL-4. At 3 and 6 d, cell phe-
notype was evaluated by FACS® analysis. Each bar is
representative of four separate experiments. (B) Ef-
fects of different doses of type I IFN. Freshly isolated
monocytes were isolated, cultured with cytokines,
and analyzed for antigen expression on day 3, as de-
scribed in Materials and Methods. Representative
data from one out of three experiments are shown.
(C) Effects of various preparations of type I IFN.
Cultures were treated with 500 U/ml of GM-CSF
and 1,000 U/ml of type I IFN, as indicated. FACS®
analysis was performed on day 3.
Figure 2. Phenotype of
monocyte-derived DCs after 3 d
of cytokine treatment. (A) Rep-
resentative dot histogram FACS®
profiles. Dotted lines represent
the staining with isotype-
matched control antibodies. (B)
Dot plot FACS® analysis of DCs
generated in the presence
CIFN/GM-CSF for 3 d. Cells
were double stained with an an-
tibody to CD83 in conjunction
with a panel of antibodies to
characterize the CD831 DC
population. 
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IL-4/GM-CSF–cultured DCs (2–5%). As shown in Fig. 2
B, CD83
 
1
 
 cells constituted a discrete population, largely
CD14
 
2
 
CD1a
 
2
 
. Moreover, further characterization dem-
onstrated that CD83 was consistently associated with high
levels of CD86 and HLA-DR expression (Fig. 2 B). These
data suggested that IFN treatment not only induced an up-
regulation of costimulatory molecules, but also promoted
the appearance of partially activated CD83
 
1
 
 DCs. The irre-
versible commitment of IFN-treated cultures to undergo
an advanced maturation process was suggested by the find-
ing that, upon cytokine removal, these cells retained a DC
phenotype without adhering to the plastic surface, whereas
IL-4/GM-CSF–treated cells reacquired the macrophage
features and readily readhered to culture plates within 3 d,
unless preventively stimulated to terminally differentiate by
LPS (data not shown). IFN/GM-CSF–treated cells proved
to be fully susceptible to undergo activation/terminal dif-
ferentiation after LPS treatment, as revealed by the en-
hanced expression of accessory molecules (data not shown)
as well as by a massive CD83 induction (Fig. 3 A).
DCs produce a series of cytokines implicated in the initi-
ation of the immune response, especially when activated by
mutual interaction with T cells or by encounter with viral
pathogens and bacterial products. Thus, it was of interest to
evaluate whether IFN/GM-CSF–cultured DCs exhibited
any specific pattern of cytokine expression compared with
cells cultured in the presence of IL-4/GM-CSF. Compara-
tive RT-PCR analysis (Fig. 3 B) showed that IFN/GM-
CSF DCs expressed high levels of mRNA for IL-1
 
b
 
.
 
Notably, induction of IL-15 expression was selectively de-
 
tected in cultures treated with IFN/GM-CSF. As IL-15
expression is tightly regulated at the translational level, it
was of interest to determine whether detectable levels of
the cytokine could be revealed in the supernatants of IFN-
treated cultures. As illustrated in Fig. 3 C, remarkable levels
of IL-15 were secreted in response to the IFN/GM-CSF
treatment. The cytokine expression pattern observed in IFN-
treated cultures resembled that observed in LPS-stimulated
DCs. At the mRNA level, similar IL-12 p40 transcript lev-
els were usually detected in response to LPS stimulation of
both IFN/GM-CSF– and IL-4/GM-CSF–cultured DCs.
As type I IFN pretreatment had been shown to differen-
tially affect the LPS-stimulated production of IL-12 p40
subunit and the bioactive p70 heterodimer (27), we also as-
sessed the production of the bioactive form of IL-12 at the
protein level. As shown in Fig. 3 C, comparable levels of
IL-12 (p70) were detected by ELISA in supernatants from
both types of LPS-stimulated DCs.
DC differentiation from monocytes treated with type I
IFN (500–1,000 U/ml) and GM-CSF was reproducibly
characterized by a decrease in the number of DCs recov-
ered after 6 d of culture. We then evaluated the percentage
of Annexin V-GFP
 
1
 
 cells at 3 and 5 d after cytokine treat-
ments. On day 3, DC cultures generated in the presence of
either IFN/GM-CSF or IL-4/GM-CSF both exhibited
low levels of Annexin V-GFP
 
1
 
 cells (i.e., 
 
z
 
7–12%). Nota-
bly, 40% of the IFN/GM-CSF DCs were stained with An-
nexin V-GFP on day 5, revealing an intrinsic attitude of a
considerable portion of these cells to undergo apoptosis
(Fig. 4 A). In contrast, only a small fraction (
 
z
 
10%) of cells
Figure 3. Induction of terminal maturation
and cytokine expression in DCs activated with
LPS. (A) Dot histogram FACS® profiles show-
ing CD83 expression upon LPS stimulation.
Monocytes were cultured with the cytokine
combinations for 5 d before performing FACS®
analysis. LPS (1 mg/ml) was added on day 3.
(B) RT-PCR analysis of cytokine mRNA ex-
pression in DCs generated in the presence of ei-
ther CIFN/GM-CSF or IL-4/GM-CSF acti-
vated or not by LPS. Cultures were treated as
described for A. RNAs were extracted on day 5
and RT-PCR was performed as described in
Materials and Methods. (C) Secretion of IL-15
and bioactive IL-12 p70 in DC supernatants.
Cell supernatants were collected at the time of
RNA extraction (B), and ELISAs were per-
formed as described previously. 
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treated with IL-4/GM-CSF were stained with Annexin
V-GFP at this time point. Thus, it was of interest to investi-
gate whether IFN could induce the expression of genes in-
volved in apoptotic pathways. As assessed by FACS
 
®
 
 analy-
sis, both types of DC cultures expressed comparable Fas
levels, whereas FasL expression was not detected (Fig. 3 B).
The expression of the novel apoptosis-inducing molecule
TRAIL, which has recently been shown to be induced by
both IFN-
 
a
 
 and IFN-
 
g
 
 (23, 28) and its receptors was eval-
uated by RT-PCR analysis. Comparative RT-PCR analy-
sis revealed a significant induction of TRAIL expression in
IFN/GM-CSF DCs, which was virtually absent in standard
IL-4/GM-CSF DCs unless activated by LPS treatment
(Fig. 4 C). Both TRAIL and the functionally active
TRAIL receptors (R1 and R2) were upregulated in re-
sponse to LPS treatment.
The possible function of TRAIL expression on DCs
generated in the presence of IFN/GM-CSF was evaluated
by experiments of DC-mediated killing of human Jurkat
cells, which are susceptible to TRAIL-induced cell death.
As shown in Fig. 4 D, DCs generated in the presence of
IFN/GM-CSF were capable of inducing apoptotic cell
death in a remarkable percentage of Jurkat cells. The in-
volvement to TRAIL expression on DCs in the induction
of apoptosis in target cells was revealed by the finding that
apoptotic cell death of Jurkat cells was inhibited by the sol-
uble inhibitor TRAIL-R2/Fc (Fig. 4 D).
 
Functional Activities of DCs Generated from IFN/GM-CSF–
treated Monocytes in Vitro and in the Hu-PBL-SCID
Mouse Model
Enhanced Allostimulatory Properties of DCs Generated in the
Presence of IFN/GM-CSF.
 
Next, we performed a series of
functional experiments aimed at comparing the ability of
DCs generated from monocytes treated with IFN/GM-
CSF to stimulate allogeneic MLRs and to induce IFN-
 
g
Figure 4. Enhanced apoptosis and induction of TRAIL expression in DCs generated with CIFN (1,000 U/ml) and GM-CSF (500 U/ml). (A) Dot his-
togram profiles showing Annexin V-GFP staining of apoptotic cells in DCs generated in the presence of either CIFN/GM-CSF or IL-4/GM-CSF cul-
tures, analyzed after 5 d of cytokine treatment. (B) FACS® profiles of Fas and FasL expression in monocyte-derived DCs. Dotted lines represent the stain-
ing with isotype-matched control antibodies. Cells were analyzed on day 5 of culture. (C) RT-PCR analysis of TRAIL and TRAIL receptors in DCs
treated or not with LPS. Monocytes were cultured with the cytokine combinations for 5 d before performing RNA extraction. LPS (1 mg/ml) was added
on day 3. RT-PCR was performed as described in Materials and Methods. (D) DC-mediated killing of Jurkat cells and evaluation of the functional signif-
icance of TRAIL expression. Monocytes were cultured in the presence of IFN/GM-CSF for 5 d, washed, and resuspended in complete medium. Jurkat
cells were cultured for 12 h in complete medium alone or in the presence of sTRAIL or IFN/GM-CSF DCs (E/T ratio 4:1). To evaluate the TRAIL in-
volvement in the DC-mediated induction of apoptosis in target cells, in some cultures TRAIL-R2/Fc was added to DC effector cells 15 min before the
addition of Jurkat cells. Phosphatidylserine externalization was monitored by Annexin V-GFP binding on gated Jurkat cells, as described in Materials and
Methods. The percentage of Annexin V-GFP1 cells is indicated for each condition. Similar results were obtained in two additional experiments.1783 Santini et al.
production by allogeneic PBLs with respect to DCs ob-
tained after IL-4/GM-CSF stimulation. In a first set of
experiments, we evaluated the proliferative response of
monocyte-depleted PBLs when cocultured with different
numbers of allogeneic DCs generated in the presence of ei-
ther IFN/GM-CSF or IL-4/GM-CSF. As shown in Fig. 5
A, at all the stimulator/responder ratios, DCs obtained in
the presence of GM-CSF and CIFN (1,000 U/ml) showed
a stronger capability to simulate the proliferation of alloge-
neic lymphocytes than IL-4/GM-CSF DCs. In subsequent
experiments, a stimulator/responder ratio of 1:20 was gen-
erally used. As illustrated in Fig. 5 B, a strong proliferative
response, as evaluated by [3H]thymidine incorporation as-
say, was observed in MLR experiments using IFN/GM-
CSF DCs. In contrast, DCs generated from the same donor
in the presence of 100 U/ml IFN elicited a poor prolifera-
tive response. This was not unexpected, as DCs generated
with 100 U/ml IFN exhibited very low levels of costimu-
latory molecules, as determined by flow cytometric analysis
(Fig. 1 B). A specific feature of MLRs generated with DCs
developed in the presence of type I IFNs was the consider-
able IFN-g production, which was definitively higher than
that found in the corresponding cocultures using DCs gen-
erated by the IL-4/GM-CSF addition (Fig. 5 C), suggest-
ing a prominent capability of IFN/GM-CSF DCs to pro-
mote a Th1 response.
Primary Response to HIV Antigens Elicited by IFN/GM-
CSF DCs In Vitro: Comparison with the Activity of DCs Gen-
erated in the Presence of IL-4/GM-CSF. We then evaluated
the ability of DCs generated in the presence of either IFN/
GM-CSF or IL-4/GM-CSF to initiate a primary response
in autologous PBLs by using inactivated HIV-1 as an im-
munogen. To inactivate HIV, we followed a recently
described procedure consisting in the use of 2,29-dithio-
dipyridine (AT-2), which inactivates HIV by selectively
disrupting the p7 nucleocapsid (NC) protein, leaving intact
the conformation and fusogenic activity of the gp120 HIV-1
protein (24). Autologous PBLs were stimulated with DCs
pulsed with AT-2–inactivated HIV-1. We evaluated the
priming activity of DCs generated in the presence of either
IFN/GM-CSF or IL-4/GM-CSF for 3 d, pulsed with inac-
tivated HIV-1 and cocultivated with autologous PBLs. Vi-
rus-pulsed IFN/GM-CSF DCs not only proved to be bet-
ter stimulators of [3H]thymidine uptake by autologous
PBLs than IL-4/GM-CSF cells (Fig. 6 A), but also induced
a stronger Th1-oriented response. In fact, the ELISPOT
analysis showed a higher number of IFN-g–producing cells
in primary cultures stimulated with IFN/GM-CSF DCs
compared with cultures stimulated with IL-4/GM-CSF
DCs (Fig. 6 B), consistent with the detection of higher lev-
els of IFN-g in culture supernatants (Fig. 6 C). Notably, lit-
tle or no secretion of IL-4 was detected in cultures stimu-
lated with virus-pulsed IFN/GM-CSF DCs, whereas
considerable amounts of this cytokine were found in the
supernatants of cultures exposed to IL-4/GM-CSF DCs
(Fig. 6 C).
Primary Antibody Response to HIV Antigens Elicited by
IFN/GM-CSF DCs in the Hu-PBL-SCID Mouse Model:
Comparison with the Activity of DCs Generated in the Presence
of IL-4/GM-CSF. The strong response elicited in vitro
by DCs pulsed with AT-2–inactivated HIV prompted us to
evaluate whether these cells could also favor an in vivo pri-
mary immunization and antibody response in SCID mice
reconstituted with human PBLs. Recent data have sug-
Figure 5. MLR assays with
DCs generated in the presence of
either CIFN/GM-CSF or IL-4/
GM-CSF. (A) Effects of different
numbers of DCs generated in the
presence of either IFN/GM-
CSF or IL-4/GM-CSF on the
proliferative response of alloge-
neic monocyte–depleted PBLs.
Monocyte-depleted PBLs were
seeded into 96-well plates at 105
cells/well. Different numbers of
purified allogeneic DCs, gener-
ated in the presence of either
CIFN/GM-CSF or IL-4/GM-
CSF for 3 d as indicated in Ma-
terials and Methods, were added
to each well. After 5 d, thymi-
dine incorporation was deter-
mined as described in Materials
and Methods. (B) DCs generated
in the presence of 1,000 U/ml of
CIFN together with GM-CSF
exhibit a potent allostimulatory capacity, whereas GM-CSF–treated cells obtained in the presence of 100 U/ml of IFN were poor stimulators in the
MLR assay. Allogeneic PBLs were stimulated by DCs (at a stimulator/responder ratio of 1:20) previously cultured for 3 d with IFN/GM-CSF or IL-4/
GM-CSF, and lymphocyte proliferation was measured as described in Materials and Methods. (C) IFN-g production in the supernatants from MLRs.
PBLs from three different donors were stimulated with allogeneic DCs generated by culturing the cells in the presence of either CIFN/GM-CSF or IL-
4/GM-CSF for 3 d (stimulator/responder ratio of 1:20). IFN-g production in the supernatants from MLRs was tested at the time of performing the lym-
phocyte proliferation assay (B). Each bar represents the value obtained with PBLs from different donors.1784 Alliance between Type I IFN and Monocyte/Dendritic Cell Development
gested that a human primary immune response can be gen-
erated in hu-PBL-SCID mice (29–32), especially when the
chimeras are injected with antigen-pulsed DCs (31). Thus,
hu-PBL-SCID mice were immunized with donor autolo-
gous DCs, pulsed for 2 h with AT-2–inactivated HIV
SF162. A boost dose was given 7 d later. At day 14, mouse
sera were collected and assayed for the presence of anti-
HIV antibodies. ELISA studies revealed the presence of
high levels of anti-gp41 antibodies in hu-PBL-SCID mice
immunized with HIV-1–pulsed DCs. Hu-PBL-SCID mice
immunized with DCs generated in the presence of IFN/
GM-CSF showed higher levels of anti-HIV antibodies than
the xenochimeras injected with DCs obtained after IL-4/
GM-CSF treatment (Fig. 7 A). At day 7, anti–HIV-1 anti-
bodies were shown to belong mainly to the IgM isotype
(Fig. 7 B). At day 14, antibodies belonging to the IgG1 iso-
type were detected especially in mice immunized with
IFN/GM-CSF–cultured DCs, thus suggesting a Th1-
biased response (Fig. 7 B). As the ELISAs used in the ex-
periments described above only detected antibodies to spe-
cific epitopes of the HIV-1 gp41 protein, it was important
to evaluate the total spectrum of human antibodies against
HIV-1 proteins by performing Western blot analysis with
pooled sera from hu-PBL-SCID mice injected with virus-
pulsed DCs. Remarkably, sera from hu-PBL-SCID mice
immunized with virus-pulsed DCs generated in the pres-
ence of IFN were capable of recognizing virtually all the
HIV-1 proteins detectable by Western blot analysis using a
human positive control serum (Fig. 7 C). Notably, sera
from immunized xenochimeras showing high levels of
anti-gp 41 antibodies effectively neutralized HIV-1 infec-
tion of activated human PBLs in vitro (data not shown).
Discussion
In this study, we have reported that type I IFNs induce a
rapid differentiation of freshly isolated GM-CSF–treated
human monocytes into short-lived DCs endowed with po-
tent functional activities both in vitro and in vivo, using the
hu-PBL-SCID mouse model. The comparison of DCs
generated in the presence of IFN/GM-CSF with those ob-
tained after the standard IL-4/GM-CSF treatment revealed
that type I IFN was definitively superior in inducing a rapid
and stable differentiation process and in conferring to DCs
a full functional activity to trigger a potent primary human
immune response both in vitro and in hu-PBL-SCID mice.
In particular, IFN induced an early detachment of mono-
cytes from culture plates, paralleled by rapid acquisition of
high levels of CD40, CD54, CD80, CD86, and HLA-DR
molecules within 3 d, whereas IL-4/GM-CSF–treated
monocytes required at least 6 d to fully acquire the imma-
ture DC phenotype. Of interest, a remarkable percentage
of CD83-expressing DCs was observed in IFN-treated cul-
tures, but not in IL-4–stimulated cells. Notably, an upregu-
lation of CD83 expression by type I IFN has been re-
ported, under very different experimental conditions, by
Figure 6. In vitro induction of a
primary immune response to HIV-1
antigens in PBLs cocultivated with au-
tologous DCs pulsed with inactivated
HIV-1. (A) DCs were generated by
standard treatment of freshly isolated
monocytes with either CIFN/GM-
CSF or IL-4/GM-CSF for 3 d as de-
scribed in Materials and Methods.
PBLs were stimulated on day 0 and re-
stimulated on day 7 with the autolo-
gous DCs pulsed with AT-2–inacti-
vated HIV-1 at a stimulator/responder
ratio of 1:4. Control cultures were in-
cubated with unpulsed autologous
DCs. Exogenous IL-2 (25 U/ml) was
added every 4 d. At day 14, the cul-
tures were restimulated with DCs
pulsed with AT-2–inactivated HIV-1,
and after 24 h [3H]thymidine was
added. Cells were harvested after an
18-h incubation. (B) The frequency of
IFN-g–producing cells was deter-
mined by enumeration of single IFN-
g–producing cells by ELISPOT, using
cells harvested at 24 h after the third
stimulation with virus-pulsed DCs.
PBLs stimulated with PHA (2 mg/ml)
were used as control (CTR). (C) Eval-
uation of IL-4 and IFN-g production
in the supernatants of primary cultures
stimulated three times with autologous
DCs. Supernatants from the cell sam-
ples described in A were tested for cy-
tokine production by ELISAs.1785 Santini et al.
Luft et al. using DCs generated from CD341 progenitor
cells (17) and recently by Radvanyi et al. (19). However,
the novel finding concerning the CD83 induction by IFN
reported in our study consists in the fact that the expression
of this marker was acquired as early as 3 d after cytokine
treatment, without any further treatment such as TNF (19)
or LPS. We also found that CD83 expression was invari-
ably associated with higher levels of HLA-DR and CD86.
Notably, the fact that IFN/GM-CSF–treated cells had ac-
quired a final commitment towards mature DC phenotype
was suggested by the finding that upon cytokine removal,
IFN/GM-CSF–treated cultures retained the DC pheno-
type, without adhering to the flask surface, whereas IL-4/
GM-CSF–treated DCs reacquired the macrophage charac-
teristics and readily readhered to culture flasks within 3 d,
unless preventively stimulated to terminally differentiate.
Of interest, the rapid differentiation observed in our IFN-
treated cultures is reminiscent of an in vitro transendothe-
lial trafficking model, in which immature DCs arose from
monocytes within 2 d (4).
In all of the experimental conditions reported in this
study, the maturation effects induced by type I IFN proved
to be superior to those achieved by the IL-4/GM-CSF
combination, as evaluated by FACS® analysis of antigen
expression as well as by both MLR assays with allogeneic
PBLs, and lymphocyte proliferation responses to autolo-
gous antigen-pulsed DCs. Three different preparations of
type I IFNs (CIFN, IFN-a2b, and IFN-b) exhibited com-
parable effects, emphasizing the general involvement of
these prototypic cytokines in the process of DC matura-
tion/activation from monocytes.
In this study, we have also reported that type I IFN in-
duces IL-15 mRNA expression and IL-15 secretion in
GM-CSF–treated DC cultures. To the best of our knowl-
Figure 7. Potent in vivo primary antibody response to HIV-1 in hu-PBL-SCID mice immunized with autologous DCs generated in the presence of
CIFN/GM-CSF and pulsed with inactivated HIV-1. (A) Human anti–HIV-1/gp41 antibodies (total Ig) in sera from hu-PBL-SCID mice immunized
and boosted (7 d later) with 1.5 3 106 DCs pulsed (2 h at 378C) with AT-2–inactivated HIV-1. Each bar represents the mean of values obtained in two
distinct experiments (eight mice in total). CTR, sera from mice reconstituted with hu-PBLs and injected with DCs generated in the presence of IFN/
GM-CSF, not pulsed with HIV-1. (B) Characterization of the Ig isotype of anti-gp41 antibodies in sera from immunized and control hu-PBL-SCID
mice. (C) Western blot analysis of antibodies against HIV-1 proteins using pooled sera from immunized hu-PBL-SCID mice. Sera from three mice for
each group were pooled. Results from two different experiments (Exp.) are shown. Western blot analysis was performed as described in Materials and
Methods. CTR(2), sera from mice reconstituted with hu-PBLs and injected with DCs generated in the presence of IFN/GM-CSF, not pulsed with
HIV-1; CTR(1), positive human serum.1786 Alliance between Type I IFN and Monocyte/Dendritic Cell Development
edge, this is the first report showing IL-15 induction by
type I IFN in monocyte-derived DCs. Notably, Zhang et
al. (33) had shown that type I IFN can induce IL-15 pro-
duction in mouse macrophages. IL-15 is a recently identi-
fied pleiotropic cytokine produced by a wide variety of
cells and tissues. This cytokine has been shown to act as a
chemoattractant for T cells (34), favoring APC–T cell in-
teraction and enhancing the generation of cytotoxic T cells
(35). IL-15 increases IFN-g production by NK and acti-
vated T cells (36) and strongly synergizes with IL-12 for
IFN-g production by upregulating IL-12Rb1 expression
on CD41 T cells (37). IL-15 mRNA has recently been
shown to be restricted to the CD831 fraction of mono-
cyte-derived DCs at late stages of DC culture (38). In fact,
DC activation is generally needed to induce IL-15 mRNA
expression in IL-4/GM-CSF–cultured DCs. At the protein
level, IL-15 production by DCs has been reported to be
low, unless triggered by phagocytic activity or cellular in-
teractions (38). In light of all this and of the recently con-
sidered involvement of IL-15 (33) in the in vivo expansion
and survival of CD81 memory T cells in mice exposed to
type I IFN (12), we may assume that IL-15 secretion in-
duced by type I IFN in DCs can represent an important
event in the adjuvant activity of IFN for the proliferation
and persistence of memory T cells in response to viral in-
fections. Of interest, IFN-treated DCs induced a strong
Th1-biased response, as evaluated by the overall cytokine
production in allogeneic MLR assays as well as in prolifera-
tion assays with HIV-1–pulsed DCs. In particular, DCs
generated in the presence of IFN/GM-CSF showed a po-
tent ability to take up, process, and present inactivated
HIV-1 to autologous T lymphocytes in vitro, which was
clearly superior to that observed using DCs cultured with
IL-4/GM-CSF. On the basis of these in vitro results, we
decided to evaluate the capability of HIV-1–pulsed DCs
generated in the presence of either IFN/GM-CSF or IL-4/
GM-CSF to elicit a primary human immune response in
vivo, by using SCID mice reconstituted with autologous
PBLs. The hu-PBL-SCID mouse model (20) has been
widely used for a variety of studies on pathogenesis (39–41)
and therapy (25) of viral infections, especially using HIV-1.
However, the generation of a primary human immune re-
sponse in the chimeras has only been reported in a very few
studies (29–32). We postulated, however, that an efficient
immune response could be elicited in hu-PBL-SCID mice
provided that appropriate antigen presentation could occur
in vivo as a result of transfusion of autologous antigen–
pulsed DCs at early times after reconstitution with hu-
PBLs. Remarkably, we found that immunization of hu-
PBL-SCID mice with IFN/GM-CSF–cultured autologous
DCs pulsed with AT-2–inactivated HIV-1 resulted in the
generation of potent primary immune response towards
HIV-1, as evaluated by the detection of specific human an-
tibodies against the whole spectrum of viral proteins (Fig.
7). At 7 d after immunization, human antibodies proved to
be mostly IgM, whereas HIV-1–specific IgG1 antibodies
were detected at 2 wk, suggesting a Th1-like response.
This may reflect the DC capability of promoting both the
generation of IgM response by naive B cells (42) and IL-
10–independent IgG1 isotype switching (43). Notably, the
antibodies detected in the sera of mice injected with DCs
generated in the presence of IFN had a potent neutralizing
activity in vitro against HIV-1. The levels of human anti-
bodies to HIV-1 were consistently higher in hu-PBL-
SCID mice injected with DCs generated in the presence of
type I IFN compared with those detected in the xenochi-
meras transplanted with the corresponding virus-pulsed
DCs developed in the presence of IL-4.
Intriguingly, even though DCs generated in the presence
of IFN showed an enhanced functional activity both in
vitro (persisting for at least 6 d) and in vivo (in the hu-
PBL-SCID mouse model), a considerable percentage of the
IFN-treated cells underwent apoptosis at 5 d of culture.
Comparative RT-PCR analysis revealed a marked induc-
tion of TRAIL expression in IFN/GM-CSF–treated DCs.
Notably, both TRAIL and functionally active receptors
TRAIL-R1 and R2 were upregulated in response to LPS
treatment. Of interest, the TRAIL expression in DCs gen-
erated in the presence of IFN/GM-CSF proved to be
functionally important in inducing apoptosis of target cells
(Fig. 4 D). In addition to IL-15 induction and CD83 up-
regulation, TRAIL upregulation represents an additional
intriguing similarity with the effects induced by LPS in
DCs. We speculate that some common signal transduction
pathways can be induced by both IFN and LPS, leading to
DC maturation. Considerable amounts of IFN (500 U/ml)
were secreted after LPS stimulation of IL-4/GM-CSF–cul-
tured DCs. Further studies are needed to clarify whether
the IFN secreted by DCs in response to LPS can play some
role in the terminal maturation of DCs.
Our results suggest the following scenario of events, with
potential new implications for vaccine research. As DCs are
the key players in the induction of the immune response, a
rapid availability of mature DCs at specific sites is of crucial
importance for an effective immune control against infec-
tions. Large amounts of type I IFN are locally produced by
specific cell types, such as natural IFN-producing cell
(NIPC)/pDC2 (8, 9), thus favoring DC development from
monocytes. Locally produced type I IFN might protect T
cells from antigen-induced apoptosis (14, 15) and induce
IL-15 production by DCs, thus favoring the proliferation
of certain T cell subsets (12, 33). Likewise, type I IFN can
also inhibit antigen-induced apoptosis of B cells (44), thus
promoting survival of antibody producing cells and en-
hancing humoral immune response. The IFN-induced up-
regulation of TRAIL expression may play a dual role: to
induce a suicide of activated DCs, as suggested by apoptosis
induction, and to induce apoptosis of virus-infected or tu-
mor cells, which have been reported to be susceptible to
TRAIL-induced apoptosis (23; Fig. 4 D). Both of these
events might be beneficial for an efficient self-controlling
host immune response against infections, and the IFN-
mediated apoptosis of DCs may represent a natural feed-
back mechanism to limit Th1 response, thus avoiding sub-
sequent tissue injury. However, the induction of TRAIL-
mediated apoptosis of virus-infected or tumor cells by DC1787 Santini et al.
generated by IFN exposure may also enhance specific im-
munity. In fact, DCs have been shown to take up apoptotic
bodies from dying cells and cross-prime cytotoxic CD81 T
cells (45). Thus, the IFN/DC-mediated apoptosis of virus-
infected or tumor cells may favor the direct priming of the
CD81 T cell response against viral or tumor antigens.
There are several important implications and perspectives
stemming from the results described above. Viruses or other
stimuli capable of inducing type I IFN (such as poly-I:C or
LPS) and CD40L, which also induce IFN production by
IL-4/GM-CSF monocyte-derived DCs (our unpublished
observations), are the strongest inducers of maturation/
activation of DCs. On the basis of the results described
above, it is reasonable to assume that the activation of the
IFN system can represent the early important mechanism
involved in the maturation/induction of DCs in response
to virus infection and possibly to other invading pathogens
or tumors.
Type I IFNs are the most used cytokines in patients with
viral and neoplastic diseases, even though the in vivo
mechanisms underlying the considerable clinical response
are still poorly understood. Notably, the current clinical use
of these cytokines does not yet imply the rationale of their
use as vaccine adjuvants. The results of this study, together
with an ensemble of data recently obtained by several
groups (10, 46), indicate that type I IFNs can represent
powerful natural adjuvants for the development of novel
vaccination strategies against virus infections and tumors.
Finally, in addition to these practical perspectives for vac-
cine development, the elucidation of the self-controlling
mechanism underlying the “alliance” between DCs and
type I IFN represents a crucial step in understanding the
basis of the early immune response to infection and under-
lines the importance of these cytokines as the natural bridge
system connecting innate and adaptive immunity.
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